Linked Life Data

19704338

Source:http://linkedlifedata.com/resource/pubmed/id/19704338

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2009-8-25
pubmed:abstractText
We examined a nonplatinum-based doublet chemotherapy regimen, pemetrexed and gemcitabine given on a biweekly (every 14 days) schedule, in patients older than 70 years with newly diagnosed advanced non-small cell lung cancer. The study was closed after nine patients were treated due to excess toxicity, primarily fatigue, and nonneutropenic infection. No responses were observed. Eight of the nine patients were hospitalized during therapy and seven discontinued treatment for reasons other than progressive disease. Median progression-free survival was 1.7 months, and median overall survival was 3.9 months. We found that biweekly pemetrexed and gemcitabine was too toxic in our cohort of elderly patients with newly diagnosed advanced non-small cell lung cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1556-1380
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1170-3
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.
pubmed:affiliation
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts 02114, USA. lvsequist@partners.org
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II